filmov
tv
Experience with Omacetaxine for TKI-Resistant TKI CML
Показать описание
Javier Pinilla-Ibarz, MD, PhD, and Camille N. Abboud, MD, discuss clinical experience using omacetaxine in chronic and accelerated phase chronic myeloid leukemia.
OncLive
cancer
oncology
Рекомендации по теме
0:03:59
Experience with Omacetaxine for TKI-Resistant TKI CML
0:08:12
Treatment Selection for Resistant or Intolerant Chronic Myeloid Leukemia
0:04:18
Omacetaxine: Old Drug With New Uses
0:06:08
Combining and Sequencing BCR-ABL TKIs with Omacetaxine in CML
0:05:27
Alternative Mechanism for Treatment of Resistant CML
0:04:31
Toxicity for Omacetaxine in CML
0:03:31
Defining Suboptimal Response to BCR-ABL TKI Therapy in CML
0:03:26
Asciminib: overcoming TKI resistance and reducing toxicity in CML
0:01:32
Fourth generation TKIs for CML: asciminib
0:14:57
Chronic Myeloid Leukemia: a curable blood cancer?
0:13:08
CHRONIC MYELOID LEUKEMIA Pathogenesis of clinical phases Accelerated phase. Blast crisis of CML
0:10:27
Expert Cancer Panel: CML chronic phase T315I mutated s/p multiple lines of therapy
0:04:12
Rationale for TKI Therapy in Relapsed CML
0:26:40
Faster, Better, Safer—Getting CML Treatment Right
0:05:31
Case 2: Additional Treatment Considerations for T315I-Mutated CML
0:17:06
Imatinib Resistant CML: Dr Marcos deLima
0:08:00
CHRONIC MYELOID LEUKEMIA Etiology. Mechanism of Tyrosine kinase pathway How BCR-ABL1 is formed
0:17:31
Debate: Chronic-Phase CML Patient Develops a T315I Mutation - Experimental Therapy
0:30:14
When can TKIs be stopped in CML?
0:10:12
Switching Therapy in Chronic Myeloid Leukemia
0:04:42
Chronic Myeloid Leukemia (CML) - Treatment - Tyrosine Kinase (TK) Inhibitors
0:00:56
Introduction
0:15:45
HOW I TREAT CML ELIAS JABBOUR
0:04:17
Gleevec mechanism of action
visit shbcf.ru